#USA #New York #Nuvation Bio #IBTROZI #safusidenib

Nuvation Bio's Q4 2025 Financial and Business Update

On March 2, 2026, Nuvation Bio Inc. (NYSE: NUVB) disclosed its financial outcomes for the fourth quarter and full year of 2025, showcasing a series of groundbreaking developments in oncology. Founded with a mission to tackle significant cancer challenges, the company has made substantial strides in the fight against non-small cell lung cancer (NSCLC) and IDH1-mutant glioma.

Key Achievements in Q4 2025

In the last quarter of 2025, Nuvation Bio successfully initiated treatment for 216 new patients using their innovative drug, IBTROZI® (taletrectinib). This brings their total to 432 patients since the drug's launch in June 2025, reflecting a substantial uptake in treatment. Healthcare professionals widely recognize the efficacy of IBTROZI for advanced ROS1-positive NSCLC, with latest data suggesting it may become a new standard of care for this patient population.

Moreover, the company reported that in Q4 alone, the treatment adoption rate for IBTROZI was approximately six times higher than similar recent launches according to IQVIA data. This robust patient enrollment underscores the growing confidence in IBTROZI among clinicians and patients alike.

On January 11, 2026, Nuvation Bio solidified its global outreach by entering into an exclusive licensing agreement with Eisai Co., Ltd., which enables the development and commercialization of taletrectinib in Europe and various other regions outside of the U.S. This partnership is expected to enhance access to innovative treatments for patients globally.

Positive Results for Safusidenib

The company also showcased promising results from a Phase 2 study on safusidenib, aimed at treating chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas. Published in Neuro-Oncology, the study reported an objective response rate (ORR) of 44%, with an impressive 88% of patients remaining progression-free at the 24-month mark. Following this success, the SIGMA study, which is pivotal for this indication, is currently underway, potentially paving the way for clinical advancements in IDH1-mutant gliomas.

Financial Health

Nuvation Bio reported a strong financial position with cash, cash equivalents, and marketable securities totaling $529.2 million as of December 31, 2025. Their revenue from IBTROZI reached approximately $15.7 million in Q4 2025, contributing to a total net product revenue of $24.7 million for the year. This significant growth primarily stems from the increasing acceptance and demand for the drug in the U.S. market.

Collaboration and license agreement revenue also saw a marked increase, rising to $26.2 million in Q4 2025 from $5.7 million in the same quarter of the previous year. Much of this increase was attributed to a $25 million milestone payment from Nippon Kayaku related to the establishment of IBTROZI's reimbursement price in Japan.

Looking Ahead

Despite experiencing a net loss of $36.6 million in Q4 2025, a decrease from $49.4 million in Q4 2024, Nuvation's financial outlook remains optimistic. For the full year 2025, the company's net loss was reported at $204.6 million compared to $567.9 million in 2024, indicating a clear trend toward stabilization and potential profitability.

Nuvation Bio is gearing up for an exciting year ahead, with a conference call scheduled for March 2, 2026, to further discuss the implications of these advancements on patient care and the company’s future strategies. As they continue to evaluate new preclinical candidates alongside potential business development opportunities, they remain steadfast in their commitment to providing effective solutions for cancer treatment.

By addressing critical unmet needs in oncology, Nuvation Bio is positioning itself as a leader in the field, with innovative therapies aimed at improving patient outcomes and advancing standards of care. The progress made with IBTROZI and safusidenib exemplifies the company's dedication to transforming the landscape of cancer therapy.